Journal
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
Volume 12, Issue 3, Pages 201-213Publisher
IVYSPRING INT PUBL
DOI: 10.7150/ijms.11047
Keywords
IDH1 protein; glioma; DNA methylation; HIF1A protein; molecular targeted therapy; review
Categories
Funding
- National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH)
Ask authors/readers for more resources
In the last five years, IDH1 mutations in human malignancies have significantly shaped the diagnosis and management of cancer patients. Ongoing intense research efforts continue to alter our understanding of the role of the IDH1 mutation in tumor formation. Currently, evidence suggests the IDH1 mutation to be an early event in tumorigenesis with multiple downstream oncogenic consequences including maintenance of a hypermethylator phenotype, alterations in HIF signalling, and disruption of collagen maturation contributing to a cancer-promoting extracellular matrix. The most recent reports elucidating these mechanisms is described in this review with an emphasis on the pathogenesis of the IDH1 mutation in glioma. Conflicting findings from various studies are discussed, in order to highlight areas warranting further research. Finally, the latest progress in developing novel therapies against the IDH1 mutation is presented, including recent findings from ongoing phase 1 clinical trials and the exciting prospect of vaccine immunotherapy targeting the IDH1 mutant protein.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available